Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis

2018-04-23 10:08:10 | BioPortfolio

Published on BioPortfolio: 2018-04-23T10:08:10-0400

Clinical Trials [486 Associated Clinical Trials listed on BioPortfolio]

Short-Course Isoniazid and Rifampin Compared With Isoniazid for Latent Tuberculosis Infection

The objective of the study was to compare the compliance and the side effects of a short course to treatment of latent tuberculosis infection during 3 months(isoniazid plus rifampin)group ...

Treatment of Latent Tuberculosis Infection With Isoniazid

The purpose of this study is to study the effect that treatment of dormant tuberculosis infection has on the immunological system. We expect to observe an impact over the production of c...

Treatment of Latent Tuberculosis in Socially Marginalised Citizens

An open-label, randomised controlled trial comparing compliance to treatment for latent tuberculosis infection in socially marginalised citizens. Participants will be randomized to either ...

A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts

There are new TB vaccines already developed that need to be tried in humans to assess their efficacy. The researchers had previously shown that production of interferon gamma by T cells i...

TBTC Study 26: Weekly RFP/INH for 3 mo. vs. Daily INH for 9 mo. for the Treatment of LTBI

The objectives of this open-label Phase III clinical trial is to compare the effectiveness and tolerability of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH...

PubMed Articles [1400 Associated PubMed Articles listed on BioPortfolio]

SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.

Currently, treatment of latent tuberculosis infection (LTBI) in Australia consists most commonly of a 9-month course of isoniazid (9H). A 3-month course of weekly isoniazid and rifapentine (3HP) has b...

Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings.

A short-course regimen of three months of weekly rifapentine and isoniazid (3HP) has recently been recommended by the World Health Organization (WHO) as an alternative to at least six months of daily ...

Prevalence of mutations in genes associated with isoniazid resistance Mycobacterium tuberculosis isolates from retreated smear positive pulmonary tuberculosis patients: A Meta-analysis.

The prevalence of isoniazid mono resistance is high in India. We investigated the molecular epidemiological characteristics association with the isoniazid resistance mutations in Mycobacterium tubercu...

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.

Treatment of latent tuberculosis infection (LTBI) is critical to the control and elimination of tuberculosis disease (TB) in the United States. In 2011, CDC recommended a short-course combination regi...

Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis.

Isoniazid is recommended for prevention of tuberculosis (TB) in HIV- infected adults but its efficacy in children living with HIV (CLHIV) is not known. We performed a systematic review to assess the e...

Medical and Biotech [MESH] Definitions

Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.

Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.

An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.

A nutritional condition produced by a deficiency of VITAMIN B 6 in the diet, characterized by dermatitis, glossitis, cheilosis, and stomatitis. Marked deficiency causes irritability, weakness, depression, dizziness, peripheral neuropathy, and seizures. In infants and children typical manifestations are diarrhea, anemia, and seizures. Deficiency can be caused by certain medications, such as isoniazid.

More From BioPortfolio on "Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis"

Quick Search


Searches Linking to this Trial